Global Liver Institute
NASH News
GLOBAL LIVER INSTITUTE
NASH Council Overview
NASH News
Resources
Membership
Stay up to date with the latest in the NASH field and subscribe to our monthly newsletters today!
How does sleep affect fatty liver disease? – NASH News
At the Academy of Managed Care Pharmacy meeting on April 16, experts discussed the emerging landscape of NASH treatments, focusing on the recent approval of Madrigal’s Rezdiffra.
GLI Celebrates US Treatment for NASH as Milestone for Liver Health – NASH News
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.
7th Annual Global Fatty Liver Day is less than 3 months away!
Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.
What’s next in line for fatty liver disease? – NASH News
Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.
GLI VP Raises NASH Awareness in the Managed Care Community – NASH News
Jeff McIntyre Raises NASH Awareness Among Health Care Community, Fatty Liver Disease More Fatal for Women, and more!
Celebrating Progress and Anticipating Success in 2024
As 2023 comes to a close, we extend our appreciation to each of you for following our monthly NASH News updates, supporting GLI’s work, and your steadfast dedication to advancing liver health. While we celebrate this year’s accomplishments, there’s more work ahead, and we eagerly anticipate another successful year in 2024.